235 related articles for article (PubMed ID: 30259374)
1. Circular RNAs in Metabolic Diseases.
Wang T; Pan W; Hu J; Zhang Z; Li G; Liang Y
Adv Exp Med Biol; 2018; 1087():275-285. PubMed ID: 30259374
[TBL] [Abstract][Full Text] [Related]
2. Circular RNAs as Potential Biomarkers and Therapeutic Targets for Metabolic Diseases.
Zaiou M
Adv Exp Med Biol; 2019; 1134():177-191. PubMed ID: 30919338
[TBL] [Abstract][Full Text] [Related]
3. Diabetes mellitus and non-alcoholic fatty liver disease: the thread of Ariadne.
Kosmidou M; Milionis H
Minerva Endocrinol; 2017 Jun; 42(2):109-121. PubMed ID: 27990792
[TBL] [Abstract][Full Text] [Related]
4. Metformin-Induced Changes of the Coding Transcriptome and Non-Coding RNAs in the Livers of Non-Alcoholic Fatty Liver Disease Mice.
Guo J; Zhou Y; Cheng Y; Fang W; Hu G; Wei J; Lin Y; Man Y; Guo L; Sun M; Cui Q; Li J
Cell Physiol Biochem; 2018; 45(4):1487-1505. PubMed ID: 29466788
[TBL] [Abstract][Full Text] [Related]
5. Long Non-Coding RNA Profiling in a Non-Alcoholic Fatty Liver Disease Rodent Model: New Insight into Pathogenesis.
Chen Y; Huang H; Xu C; Yu C; Li Y
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28275212
[TBL] [Abstract][Full Text] [Related]
6. Circular RNAs in non-alcoholic fatty liver disease: Functions and clinical significance.
Zeng Q; Liu CH; Ampuero J; Wu D; Jiang W; Zhou L; Li H; Bai L; Romero-Gómez M; Tang H
RNA Biol; 2024 Jan; 21(1):1-15. PubMed ID: 38113132
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of non-alcoholic fatty liver disease in patients with diabetes mellitus, hyperlipidemia, obesity and polycystic ovary syndrome: A cross-sectional study in north of Iran.
Mansour-Ghanaei F; Joukar F; Mobaraki SN; Mavaddati S; Hassanipour S; Sepehrimanesh M
Diabetes Metab Syndr; 2019; 13(2):1591-1596. PubMed ID: 31336526
[TBL] [Abstract][Full Text] [Related]
8. Circular RNAs in Cardiovascular Diseases.
Wang L; Meng X; Li G; Zhou Q; Xiao J
Adv Exp Med Biol; 2018; 1087():191-204. PubMed ID: 30259367
[TBL] [Abstract][Full Text] [Related]
9. The Role of Circular RNAs in Cerebral Ischemic Diseases: Ischemic Stroke and Cerebral Ischemia/Reperfusion Injury.
Yang J; Chen M; Cao RY; Li Q; Zhu F
Adv Exp Med Biol; 2018; 1087():309-325. PubMed ID: 30259377
[TBL] [Abstract][Full Text] [Related]
10. Circular RNAs in Vascular Functions and Diseases.
Ding S; Zhu Y; Liang Y; Huang H; Xu Y; Zhong C
Adv Exp Med Biol; 2018; 1087():287-297. PubMed ID: 30259375
[TBL] [Abstract][Full Text] [Related]
11. Noncoding RNAs in Vascular Diseases.
Jaé N; Dimmeler S
Circ Res; 2020 Apr; 126(9):1127-1145. PubMed ID: 32324505
[TBL] [Abstract][Full Text] [Related]
12. Obesity and metabolic syndrome as risk factors for the development of non-alcoholic fatty liver disease as diagnosed by ultrasound.
Petrović G; Bjelaković G; Benedeto-Stojanov D; Nagorni A; Brzački V; Marković-Živković B
Vojnosanit Pregl; 2016 Oct; 73(10):910-20. PubMed ID: 29327896
[TBL] [Abstract][Full Text] [Related]
13. The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity.
Ampuero J; Aller R; Gallego-Durán R; Banales JM; Crespo J; García-Monzón C; Pareja MJ; Vilar-Gómez E; Caballería J; Escudero-García D; Gomez-Camarero J; Calleja JL; Latorre M; Albillos A; Salmeron J; Aspichueta P; Lo Iacono O; Francés R; Benlloch S; Fernández-Rodríguez C; García-Samaniego J; Estévez P; Andrade RJ; Turnes J; Romero-Gómez M;
Aliment Pharmacol Ther; 2018 Dec; 48(11-12):1260-1270. PubMed ID: 30353552
[TBL] [Abstract][Full Text] [Related]
14. Metabolic disorders affecting the liver and heart: Therapeutic efficacy of miRNA-based therapies?
La Sala L; Carlini V; Conte C; Macas-Granizo MB; Afzalpour E; Martin-Delgado J; D'Anzeo M; Pedretti RFE; Naselli A; Pontiroli AE; Cappato R
Pharmacol Res; 2024 Mar; 201():107083. PubMed ID: 38309383
[TBL] [Abstract][Full Text] [Related]
15. Genome-wide analysis of long noncoding RNA expression profiles in patients with non-alcoholic fatty liver disease.
Sun C; Liu X; Yi Z; Xiao X; Yang M; Hu G; Liu H; Liao L; Huang F
IUBMB Life; 2015 Nov; 67(11):847-52. PubMed ID: 26472541
[TBL] [Abstract][Full Text] [Related]
16. [Regulatory mechanism and potential value of circular RNA in nonalcoholic fatty liver disease progression].
Xie Q; Wang LL; Wang L; Yao DF; Yao M
Zhonghua Gan Zang Bing Za Zhi; 2022 Nov; 30(11):1270-1275. PubMed ID: 36891710
[TBL] [Abstract][Full Text] [Related]
17. Nonalcoholic fatty liver disease: Evolving paradigms.
Lonardo A; Nascimbeni F; Maurantonio M; Marrazzo A; Rinaldi L; Adinolfi LE
World J Gastroenterol; 2017 Sep; 23(36):6571-6592. PubMed ID: 29085206
[TBL] [Abstract][Full Text] [Related]
18. MicroRNAs as controlled systems and controllers in non-alcoholic fatty liver disease.
Panera N; Gnani D; Crudele A; Ceccarelli S; Nobili V; Alisi A
World J Gastroenterol; 2014 Nov; 20(41):15079-86. PubMed ID: 25386056
[TBL] [Abstract][Full Text] [Related]
19. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
[TBL] [Abstract][Full Text] [Related]
20. Non-coding RNAs derailed: The many influences on the fatty acid reprogramming of cancer.
Yu XH; Wang HF; Wu JB; Wang SS; Tang YJ; Tang YL; Liang XH
Life Sci; 2019 Aug; 231():116509. PubMed ID: 31152812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
